[{"id":"543cd16b-633b-4c4e-b967-73fb1131c4b4","acronym":"LUNG-MAP Sub-Study","url":"https://clinicaltrials.gov/study/NCT03845296","created_at":"2021-01-17T17:13:03.964Z","updated_at":"2024-07-02T16:34:59.337Z","phase":"Phase 2","brief_title":"Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)","source_id_and_acronym":"NCT03845296 - LUNG-MAP Sub-Study","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • BRAF • ALK • BRCA1 • BRCA2 • ROS1 • HRD • BRCA • CD4","pipe":" | ","alterations":" BRAF V600E • BRCA2 mutation • BRCA1 mutation • EGFR mutation • BRAF V600 • EGFR T790M • HRD • ALK fusion • ROS1 fusion • HRD + BRCA1 mutation","tags":["EGFR • BRAF • ALK • BRCA1 • BRCA2 • ROS1 • HRD • BRCA • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRCA2 mutation • BRCA1 mutation • EGFR mutation • BRAF V600 • EGFR T790M • HRD • ALK fusion • ROS1 fusion • HRD + BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rubraca (rucaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 04/16/2019","start_date":" 04/16/2019","primary_txt":" Primary completion: 01/01/2022","primary_completion_date":" 01/01/2022","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-06-04"},{"id":"cdacc270-2f12-47f1-ad69-ceb4bc5981ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT03337087","created_at":"2021-01-18T16:29:08.233Z","updated_at":"2024-07-02T16:35:02.682Z","phase":"Phase 1/2","brief_title":"Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer","source_id_and_acronym":"NCT03337087","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" BRCA1 • BRCA2 • HRD • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HRD • PALB2 mutation • HRD + BRCA1 mutation","tags":["BRCA1 • BRCA2 • HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HRD • PALB2 mutation • HRD + BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Rubraca (rucaparib) • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • fluorouracil topical"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/02/2018","start_date":" 11/02/2018","primary_txt":" Primary completion: 03/31/2021","primary_completion_date":" 03/31/2021","study_txt":" Completion: 08/09/2025","study_completion_date":" 08/09/2025","last_update_posted":"2024-05-17"},{"id":"be84ddd3-f2ce-46d3-ae9d-39c0fd0d285e","acronym":"DIDO","url":"https://clinicaltrials.gov/study/NCT04983745","created_at":"2021-07-30T17:55:02.511Z","updated_at":"2024-07-02T16:35:25.580Z","phase":"Phase 2","brief_title":"Niraparib and Dostarlimab in HRD Solid Tumors","source_id_and_acronym":"NCT04983745 - DIDO","lead_sponsor":"West Cancer Center","biomarkers":" BRCA1 • BRCA2 • HRD • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A • FANCI","pipe":" | ","alterations":" BRCA1 mutation • HRD • ATM mutation • PALB2 mutation • CHEK2 mutation • BRIP1 mutation • HRD + BRCA1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation • FANCI mutation • RAD51 mutation","tags":["BRCA1 • BRCA2 • HRD • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A • FANCI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • HRD • ATM mutation • PALB2 mutation • CHEK2 mutation • BRIP1 mutation • HRD + BRCA1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation • FANCI mutation • RAD51 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • Jemperli (dostarlimab-gxly)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/29/2021","start_date":" 11/29/2021","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2023-12-21"},{"id":"e81c8424-a296-48d7-a4d2-c6f1231c20b0","acronym":"SALE","url":"https://clinicaltrials.gov/study/NCT04692740","created_at":"2021-01-19T20:48:58.009Z","updated_at":"2024-07-02T16:35:36.241Z","phase":"Phase 2","brief_title":"Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial)","source_id_and_acronym":"NCT04692740 - SALE","lead_sponsor":"Michele Reni","biomarkers":" BRCA1 • BRCA2 • HRD","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HRD • HRD + BRCA1 mutation","tags":["BRCA1 • BRCA2 • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HRD • HRD + BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Leukeran (chlorambucil)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 12/18/2020","start_date":" 12/18/2020","primary_txt":" Primary completion: 01/04/2023","primary_completion_date":" 01/04/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2023-09-21"},{"id":"33e6efe3-69ef-47f0-b007-a45c428903e9","acronym":"TRITON2","url":"https://clinicaltrials.gov/study/NCT02952534","created_at":"2021-01-17T17:39:04.239Z","updated_at":"2024-07-02T16:35:46.027Z","phase":"Phase 2","brief_title":"A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency","source_id_and_acronym":"NCT02952534 - TRITON2","lead_sponsor":"zr Pharma \u0026 GmbH","biomarkers":" BRCA1 • BRCA2 • HRD","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HRD • ATM mutation • HRD + BRCA1 mutation • BRCA1 mutation + ATM mutation","tags":["BRCA1 • BRCA2 • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HRD • ATM mutation • HRD + BRCA1 mutation • BRCA1 mutation + ATM mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rubraca (rucaparib)"],"overall_status":"Completed","enrollment":" Enrollment 277","initiation":"Initiation: 02/15/2017","start_date":" 02/15/2017","primary_txt":" Primary completion: 07/18/2021","primary_completion_date":" 07/18/2021","study_txt":" Completion: 07/27/2021","study_completion_date":" 07/27/2021","last_update_posted":"2023-06-09"},{"id":"0e367cd1-2928-4295-9ca7-329d7f1adf37","acronym":"","url":"https://clinicaltrials.gov/study/NCT05597527","created_at":"2022-10-28T15:58:18.969Z","updated_at":"2024-07-02T16:36:01.678Z","phase":"Phase 2","brief_title":"Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer","source_id_and_acronym":"NCT05597527","lead_sponsor":"Fujian Cancer Hospital","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HRD + BRCA1 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HRD + BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiTan (rivoceranib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2022-10-28"},{"id":"2a67dca9-672c-44cc-ba63-72dc0d4ee9dd","acronym":"HOPEII","url":"https://clinicaltrials.gov/study/NCT05069818","created_at":"2021-10-06T12:54:04.965Z","updated_at":"2024-07-02T16:36:23.434Z","phase":"","brief_title":"Variance of HRD From Paired Ovarian Cancer","source_id_and_acronym":"NCT05069818 - HOPEII","lead_sponsor":"Xiaoxiang Chen","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HRD • BRCA wild-type • HRD + BRCA1 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HRD • BRCA wild-type • HRD + BRCA1 mutation"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 10/01/2022","primary_completion_date":" 10/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2021-10-06"},{"id":"ba24ef7d-1f4f-49ea-9992-e392030963e9","acronym":"POLA","url":"https://clinicaltrials.gov/study/NCT02684318","created_at":"2021-01-19T11:44:36.764Z","updated_at":"2025-02-25T14:57:32.272Z","phase":"Phase 1/2","brief_title":"Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors","source_id_and_acronym":"NCT02684318 - POLA","lead_sponsor":"Poveda, Andrés, M.D.","biomarkers":" BRCA1 • PTEN • PARP1","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HRD + BRCA1 mutation","tags":["BRCA1 • PTEN • PARP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HRD + BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Zepzelca (lurbinectedin)"],"overall_status":"Unknown status","enrollment":" Enrollment 100","initiation":"Initiation: 07/01/2015","start_date":" 07/01/2015","primary_txt":" Primary completion: 07/01/2019","primary_completion_date":" 07/01/2019","study_txt":" Completion: 10/01/2019","study_completion_date":" 10/01/2019","last_update_posted":"2017-06-22"}]